The Medical Advisor

Vision assistance smart glasses are redefining independence for people who are blind or living with low vision. In 2026, breakthroughs in AI vision models, lightweight optics, and real-time scene understanding have transformed smart glasses from simple magnifiers into powerful assistive AI devices . There is no single "best" smart glasses for visual impairment in 2026 — the right pick depends on how much usable vision remains. For low vision (residual central vision from macular degeneration, diabetic retinopathy, or Stargardt disease), medical-grade enhancers like eSight Go ($4,950) or Acesight VR digitally magnify and boost contrast. For blind or near-blind users, AI-interpretation glasses like Envision Glasses ($2,499), OrCam MyEye 3 Pro ($4,490), or the budget-friendly Ally Solos (from $399) read text and describe scenes aloud. A newer, cheaper option — Meta Ray-Ban / Meta AI Glasses (from $299) — isn't purpose-built for accessibility but has become a popular everyda...

Abstract Background: Lung cancer, particularly advanced or metastatic non–small cell lung cancer (NSCLC) and small-cell lung cancer (SCLC), remains a leading cause of cancer mortality worldwide. Conventional therapies such as targeted agents, immunotherapy, and chemotherapy offer survival benefits but often yield limited results in treatment-resistant or late-stage disease. Repurposing widely available antiparasitic drugs — fenbendazole , ivermectin , and mebendazole — has garnered attention in integrative oncology communities due to reported anticancer effects in preclinical studies and emerging anecdotal clinical observations. Objective: To summarize a compilation of real-world case reports describing the use of fenbendazole, ivermectin, and mebendazole in lung cancer patients, highlighting reported clinical outcomes and therapeutic contexts. Methods: This review synthesizes case narratives and outcome descriptions publicly shared through online platforms, including clinicians...